Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.
Saved in:
| Title: | Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure. |
|---|---|
| Authors: | Spreafico A; Department of Medicine, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada., Couselo EM; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Irmisch A; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Bessa J; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Au-Yeung G; Department of Medical Oncology, Peter MacCallum Cancer Center and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia., Bechter O; Department of General Medical Oncology, Universitair Ziekenhuis (UZ), Leuven, Leuven, Belgium., Svane IM; National Center for Cancer Immune Therapy and Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Sanmamed MF; Department of Medical Oncology, Clínica Universidad de Navarra and Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Gambardella V; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain., McKean M; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, United States., Callahan M; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, United States., Dummer R; Department of Dermatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland., Klein C; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Umaña P; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Justies N; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Heil F; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany., Fahrni L; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Opolka-Hoffmann E; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany., Waldhauer I; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Bleul C; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland., Staack RF; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany., Karanikas V; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Fowler S; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland. |
| Source: | Frontiers in oncology [Front Oncol] 2024 Mar 21; Vol. 14, pp. 1346502. Date of Electronic Publication: 2024 Mar 21 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38577337 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Spreafico+A%22">Spreafico A</searchLink>; Department of Medicine, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Couselo+EM%22">Couselo EM</searchLink>; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Irmisch+A%22">Irmisch A</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bessa+J%22">Bessa J</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Au-Yeung+G%22">Au-Yeung G</searchLink>; Department of Medical Oncology, Peter MacCallum Cancer Center and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Bechter+O%22">Bechter O</searchLink>; Department of General Medical Oncology, Universitair Ziekenhuis (UZ), Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Svane+IM%22">Svane IM</searchLink>; National Center for Cancer Immune Therapy and Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.<br /><searchLink fieldCode="AU" term="%22Sanmamed+MF%22">Sanmamed MF</searchLink>; Department of Medical Oncology, Clínica Universidad de Navarra and Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Gambardella+V%22">Gambardella V</searchLink>; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22McKean+M%22">McKean M</searchLink>; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, United States.<br /><searchLink fieldCode="AU" term="%22Callahan+M%22">Callahan M</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, United States.<br /><searchLink fieldCode="AU" term="%22Dummer+R%22">Dummer R</searchLink>; Department of Dermatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Klein+C%22">Klein C</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Umaña+P%22">Umaña P</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Justies+N%22">Justies N</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Heil+F%22">Heil F</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Fahrni+L%22">Fahrni L</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Opolka-Hoffmann+E%22">Opolka-Hoffmann E</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Waldhauer+I%22">Waldhauer I</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bleul+C%22">Bleul C</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Staack+RF%22">Staack RF</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Karanikas+V%22">Karanikas V</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Fowler+S%22">Fowler S</searchLink>; Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2024 Mar 21; Vol. 14, pp. 1346502. <i>Date of Electronic Publication: </i>2024 Mar 21 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38577337 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fonc.2024.1346502 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1346502 Titles: – TitleFull: Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Spreafico A – PersonEntity: Name: NameFull: Couselo EM – PersonEntity: Name: NameFull: Irmisch A – PersonEntity: Name: NameFull: Bessa J – PersonEntity: Name: NameFull: Au-Yeung G – PersonEntity: Name: NameFull: Bechter O – PersonEntity: Name: NameFull: Svane IM – PersonEntity: Name: NameFull: Sanmamed MF – PersonEntity: Name: NameFull: Gambardella V – PersonEntity: Name: NameFull: McKean M – PersonEntity: Name: NameFull: Callahan M – PersonEntity: Name: NameFull: Dummer R – PersonEntity: Name: NameFull: Klein C – PersonEntity: Name: NameFull: Umaña P – PersonEntity: Name: NameFull: Justies N – PersonEntity: Name: NameFull: Heil F – PersonEntity: Name: NameFull: Fahrni L – PersonEntity: Name: NameFull: Opolka-Hoffmann E – PersonEntity: Name: NameFull: Waldhauer I – PersonEntity: Name: NameFull: Bleul C – PersonEntity: Name: NameFull: Staack RF – PersonEntity: Name: NameFull: Karanikas V – PersonEntity: Name: NameFull: Fowler S IsPartOfRelationships: – BibEntity: Dates: – D: 21 M: 03 Text: 2024 Mar 21 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 2234-943X Numbering: – Type: volume Value: 14 Titles: – TitleFull: Frontiers in oncology Type: main |
| ResultId | 1 |
